STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Tailored radiation beams aim to shrink liver tumors without harming healthy tissue
Disease control OngoingThis study tests whether giving a personalized dose of Yttrium-90 radiation to liver cancer patients can better shrink tumors while protecting healthy liver tissue. About 42 adults with advanced liver cancer that cannot be removed by surgery will receive a custom treatment plan b…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 12:09 UTC
-
New drug combo shows promise against tough bile duct cancer
Disease control OngoingThis phase 2 trial tests whether adding pevonedistat to standard chemotherapy (carboplatin and paclitaxel) can shrink tumors in people with advanced bile duct cancer that has spread or cannot be removed. About 40 adults whose cancer progressed after gemcitabine-based chemo will r…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
New combo shows promise for High-Risk liver cancer
Disease control OngoingThis study tests whether combining regorafenib (a drug that blocks cancer cell growth) with durvalumab (an immunotherapy that helps the immune system attack cancer) can shrink tumors in people with high-risk liver cancer. Four adults with stage IB to IIIA liver cancer are partici…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
Engineered immune cells take on Hard-to-Treat liver cancer
Disease control TerminatedThis early-phase trial tests a new treatment called RPCAR01 for people with advanced liver cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein call…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial tested the safety of combining two drugs, nivolumab and cabozantinib, in 8 people with HIV who also have advanced solid tumors. The goal was to see if the combination is safe and can shrink or stabilize the cancer. The study focused on finding the right dos…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC
-
Immunotherapy duo after radiation shows promise for untreatable liver cancer
Disease control OngoingThis early-stage trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) after a targeted radiation treatment can help control advanced liver cancer that cannot be removed by surgery. The study involves 25 adults with liver cancer that has spread locally.…
Matched conditions: STAGE III HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC